Chen Yang
About
Chen Yang is from New York City Metropolitan Area. Chen works in the following industries: "Biotechnology Research". Chen is currently Senior Director, Head of R&D at CyanVaccine. In Chen's previous role as a AI + Medicine Research Scientist of Theta Team at Monash University, Chen worked in until Feb 2026. Prior to joining Monash University, Chen was a Volunteer Researcher at University of Washington and held the position of Volunteer Researcher. Prior to that, Chen was a Senior Director, Early Discovery at Codagenix Inc., based in New York and Boston, United States from Jul 2021 to Nov 2025. Chen started working as Researcher at Harvard Medical School in Cambridge, Massachusetts, United States in Jun 2023. From Aug 2022 to Sep 2024, Chen was Innovator at Harvard Innovation Labs, based in Boston, Massachusetts, United States. Prior to that, Chen was a Director, Virus Research and BD at Codagenix, Inc. from Nov 2020 to Jul 2021. Chen started working as Director, Virus Research at Codagenix, Inc. in Farmingdale, NY in Jan 2019.
Go to finalscout.com and type Chen Yang's name into the search box for a free email address. FinalScout is a professional database with more than 500 million business professionals and 200 million company executives.
Chen Yang's current jobs
Lead discovery, preclinical development, and translational R&D across a multi-program vaccine and biologics portfolio, including clinical stage adult and pediatric RSV programs, spanning early discovery, PCC advancement, IND-enabling studies, CMC material evaluation, and clinical assay development. Discovery & Pipeline Strategy - Lead an early discovery team developing four new programs, including vector based vaccine candidates, and therapeutic oncology products. - Drive program strategy, experimental design, animal model selection, proof-of-concept planning, and preclinical candidate advancement. Preclinical Development & IND-Enabling Execution - Lead IND-enabling development of a mature PCC program, supporting both adult and pediatric regulatory pathways. - Oversee internal pharmacology, efficacy, immunogenicity, genetic stability, and translational studies, while coordinating outsourced safety studies and selected in-house nonclinical assessments. CMC Interface & Product Evaluation - Serve as the R&D interface with CMC for biological and nonclinical evaluation of pilot, engineering, and clinical-grade drug product lots. - Oversee genetic stability, biological characterization, potency-related assessment, and in vivo efficacy evaluation of CMC-manufactured materials. Clinical Assay Development - Lead clinical analytical method development for immunogenicity, virology, and translational endpoints to support adult and pediatric clinical programs. - Partner with CMC, regulatory, clinical, quality, CROs, and senior leadership to advance programs from discovery through IND-enabling development and clinical assay readiness.
Chen Yang's past jobs
Remote researcher in Theta Team, working on AI in Medicine. Project 1: LLM in vaccine, with focus on antibody binder design. Project 2: LLM in immunogenicity prediction, and risk management in R&D.
• Mentored a team of 5+ students in data mining and machine learning projects on healthy diet markers and racial disparities using NHANES databases. • Led a team of 6 scientists in cardiovascular disease simulation modeling project, contributing to health policy development. • Team member of AI-Health Policy group to generate policy memos using the LLM model, based on scientific research articles. • Collaborated with faculty members to align projects with R01 research goals.
Early Discovery: Lead vaccine R&D-RSV, Influenza, Dengue, Yellow Fever, COVID, Zika, VSV; Translational: Preclinical to IND - RSV pediatric Phase 1 trial, elderly Phase 1 trial. Influenza Phase 1 trial. COVID-19 Phase 1 to Phase 3 trials. IP development: Develop PCT patents (>9). Manuscript and grants: Draft and manage scientific manuscripts, government and NGO grant application. Machine Learning: prediction model for immunogenicity, facilitate vaccine RNA design (Python, R).
Project 1: Financial Toxicity and Its Impact on Mental Health Outcomes in Cancer Survivors During the COVID-19 Pandemic Project 2: Efficacy of glutamatergic medications for obsessive-compulsive and related disorders: A systematic review and meta-analysis Project 3: Utilizing machine learning to analyze immune responses to influenza infection, evaluate the temporal immunogenicity, potency, and breadth of influenza vaccines, and develop models and predictions for pandemic preparedness (generalized additive model, Fourier transform, decision tree, random forest, neural network).
HiDr.AI: An AI-driven healthcare tech venture dedicated to improving behavioral health outcomes for Medicaid recipients. Our platform ensures equal access to healthcare providers for patients while streamlining the process for psychologists and psychiatrists to connect with their patients. Additionally, we manage claims and billing efficiently, making the healthcare experience smoother for all parties involved.
Lead R&D of infectious disease and oncolytic virus pipeline, including human viruses of RSV, dengue, influenza, Yellow Fever and animal vaccines; Design business strategy for with Chief Business Officer; Build R&D strategy with CSO.
Developed world first live attenuated coronavirus vaccine for COVID-19 (SARS-2-CoV) (Phase 3 trial); Expand our pipeline of synthetic oncolytic virus and viral vector; R&D for next generation influenza virus, dengue virus, zika virus, yellow fever virus and RSV vaccine;
Immunotherapy: Developed a novel oncolytic platform patent using synthetic biology method; Built oncolytic animal models including glioblastoma, neuroblastoma, bladder cancer, breast cancer, non-small cell lung cancer and liver cancer. Vaccine: Led novel animal vaccines R&D; Led the pre-clinical research for human influenza vaccine; Developed synthetic biology and live attenuated vaccine platform patents;
As a Principal Investigator won NIH REACH Grant: A novel glioblastoma drug – Oncolytic virus Mono-Cre PV1(M). Led the translational research of commercializing a second generation poliovirus as an oncolytic virus to surpass our original designed FDA breakthrough therapy agent PVS-RIPO.
Biotech using synthetic biology to molecular engineer virus and microbe for energy sector and oncology R&D.